Skip to main content
SpringerLink
Log in

Management of Localized Low-Grade Follicular Lymphoma

  • Chapter
  • First Online:
Follicular Lymphoma

Abstract

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. A long natural history and an evolution in staging modalities and treatment options has complicated studies regarding its optimal management. As a result, there is great variety in the therapeutic approaches used for low-grade (grade 1–2) early-stage FL. Definitive radiation therapy (RT) to a generous involved site volume to 24 Gy remains the recommended treatment for patients with stage I or contiguous stage II disease, based on retrospective data demonstrating prolonged disease-free intervals and even cure. An alternative is an even lower-dose RT to 4 Gy, which results in high response rates, with less toxicity but inferior local control. Additionally, observation may be appropriate in selected cases. The use of immunochemotherapy may improve progression-free survival (PFS) when added to RT but does not appear to affect overall survival, so its use in combination with RT or alone remains under investigation. This chapter review focuses on current understanding of these issues in localized grade 1–2 FL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.

    Article  CAS  Google Scholar 

  2. Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–8.

    Article  Google Scholar 

  3. Tsang RW, Gospodarowicz MK. Low-grade non-Hodgkin lymphomas. Semin Radiat Oncol. 2007;17(3):198–205.

    Article  Google Scholar 

  4. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368–75.

    Article  CAS  Google Scholar 

  5. Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10(4):489–97.

    Article  CAS  Google Scholar 

  6. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–90.

    Article  CAS  Google Scholar 

  7. Kamath SS, Marcus RB Jr, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 1999;44(3):563–8.

    Article  CAS  Google Scholar 

  8. Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928–34.

    Article  Google Scholar 

  9. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–806.

    Article  Google Scholar 

  10. Brady JL, Binkley MS, Hajj C, Chelius MR, Chau KW, Levis M, et al. Outcome of curative radiotherapy for localised follicular lymphoma in the era of 18F-FDG PET-CT staging: an international collaborative study on behalf of ILROG. Hematol Oncol. 2017;35(S2):29–31.

    Article  Google Scholar 

  11. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.

    Article  Google Scholar 

  12. Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–63.

    Article  Google Scholar 

  13. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86(5):930–5.

    Article  Google Scholar 

  14. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39(6):1095–100.

    Article  Google Scholar 

  15. Goda JS, Le LW, Lapperriere NJ, Millar BA, Payne D, Gospodarowicz MK, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81(4):e659–66.

    Article  Google Scholar 

  16. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.

    Article  Google Scholar 

  17. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21(11):2115–22.

    Article  CAS  Google Scholar 

  18. Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer. 1993;71(7):2342–50.

    Article  CAS  Google Scholar 

  19. Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19–25.

    Article  CAS  Google Scholar 

  20. Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I–II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94(4):783–91.

    Article  CAS  Google Scholar 

  21. Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56(8):2350–6.

    Article  CAS  Google Scholar 

  22. Michallet AS, Lebras LL, Bauwens DD, Bouafia-Sauvy FF, Berger FF, Tychyj-Pinel CC, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol. 2013;6:45.

    Article  CAS  Google Scholar 

  23. Mondello P, Steiner N, Wasle I, Pitini V, Mian M. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? Anticancer Res. 2014;34(11):6701–4.

    PubMed  Google Scholar 

  24. Barzenje DA, Cvancarova Smastuen M, Liestol K, Fossa A, Delabie J, Kolstad A, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One. 2015;10(7):e0131158.

    Article  Google Scholar 

  25. Sancho JM, Garcia O, Mercadal S, Pomares H, Fernandez-Alvarez R, Gonzalez-Barca E, et al. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leuk Res. 2015;39(8):853–8.

    Article  Google Scholar 

  26. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–5.

    Article  CAS  Google Scholar 

  27. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116(16):3843–51.

    Article  Google Scholar 

  28. Soubeyran P, Eghbali H, Trojani M, Bonichon F, Richaud P, Hoerni B. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7(7):713–8.

    Article  CAS  Google Scholar 

  29. Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–53.

    Article  Google Scholar 

  30. Yuda S, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto KI, et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol. 2016;95(12):2017–22.

    Article  CAS  Google Scholar 

  31. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454–9.

    Article  Google Scholar 

  32. (NCCN) NCCN. NCCN Clinical practice guidelines in oncology. B-cell lymphomas version 5.2017. In: Network. NCC, editor. 2017.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Southwestern, Department of Radiation Oncology, Dallas, TX, USA

    Neil B. Desai

  2. MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX, USA

    Sarah A. Milgrom

Authors
  1. Neil B. Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah A. Milgrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah A. Milgrom .

Editor information

Editors and Affiliations

  1. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nathan H. Fowler

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Desai, N.B., Milgrom, S.A. (2020). Management of Localized Low-Grade Follicular Lymphoma. In: Fowler, N. (eds) Follicular Lymphoma. Springer, Cham. https://doi.org/10.1007/978-3-030-26211-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26211-2_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26210-5

  • Online ISBN: 978-3-030-26211-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation